Physician profile
Anna Gut
NPI 1740611748
$9,424.07
in general payments reported to CMS, 2019-2025
18 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 93% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,318 · 2022: $2,279 · 2023: $2,352 · 2024: $1,627 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,826.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,845.00 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,452.48 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,184.14 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $897.46 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $835.90 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $683.26 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $608.78 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $458.52 | 2022-2024 | Uzedy, Austedo Xr |
| Corium, LLC | $259.28 | 2023-2024 | Azstarys, Azstarys |
| E.R. Squibb & Sons, L.L.C. | $242.06 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $234.68 | 2021 | |
| Tms Neurohealth Centers INC. | $143.59 | 2025 | Tms Neurohealth Centers INC. |
| Lilly USA, LLC | $124.17 | 2025 | Zepbound |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $120.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.62 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $112.64 | 2021-2025 | Trintellix |
| Eisai INC. | $84.42 | 2021 | |
| Lundbeck LLC | $23.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Gut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.